Caplin Point gets 2 USFDA observations for sterile injectable site in Chennai
The US Food and Drug Administration (USFDA) has completed inspection of Caplin Steriles Ltd's site at Gummidipoondi in Tamil Nadu, between June 6-14, 2019.
New Delhi: Caplin Point Laboratories on Monday said the US health regulator has made two observations after completion of inspection at its subsidiary's sterile injectable site in Tamil Nadu.
The US Food and Drug Administration (USFDA) has completed inspection of Caplin Steriles Ltd's site at Gummidipoondi in Tamil Nadu, between June 6-14, 2019.
At the end of this scheduled Good Manufacturing Practice (GMP) inspection, there were only two observations, Caplin Point Laboratories said in a BSE filing.
New Delhi: Caplin Point Laboratories on Monday said the US health regulator has made two observations after completion of inspection at its subsidiary's sterile injectable site in Tamil Nadu.
The US Food and Drug Administration (USFDA) has completed inspection of Caplin Steriles Ltd's site at Gummidipoondi in Tamil Nadu, between June 6-14, 2019.
At the end of this scheduled Good Manufacturing Practice (GMP) inspection, there were only two observations, Caplin Point Laboratories said in a BSE filing.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd